Skip to main content
Top
Gepubliceerd in:

01-04-2019 | Nursing challenge

Immuuntherapie

Auteurs: Janneke van der Stap, Anne van Lindert

Gepubliceerd in: Nursing | Uitgave 4/2019

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Kanker ontstaat door problemen in het immuunsysteem. Daarom wordt tegen steeds meer kankersoorten immuuntherapie ingezet. In dit artikel aandacht voor checkpoint inhibitors. Met de toets verdien je 2 accreditatiepunten.
Literatuur
1.
go back to reference Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature, 2011 Dec 21; 480: 480-489. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature, 2011 Dec 21; 480: 480-489.
2.
go back to reference Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest, 2015 Sept 1; 125(9): 3335-3337. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest, 2015 Sept 1; 125(9): 3335-3337.
3.
go back to reference Couzin-Frankel J, Breakthrough of the year 2013. Cancer immunotherapy. Science, 2013 Dec 20: 342: 1432-3. Couzin-Frankel J, Breakthrough of the year 2013. Cancer immunotherapy. Science, 2013 Dec 20: 342: 1432-3.
4.
go back to reference Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, Aug 19; 363: 711-723. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, Aug 19; 363: 711-723.
5.
go back to reference Hossein Borghaei DO et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small cell lung cancer. N Engl J Med 2015, Oct 22; 373: 1627-1639. Hossein Borghaei DO et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small cell lung cancer. N Engl J Med 2015, Oct 22; 373: 1627-1639.
6.
go back to reference Rijkers GT, Kroese FGM, Kallenberg CGM, et al. Leerboek immunologie. Houten: Bohn Stafleu van Loghum; 2016: 493. Rijkers GT, Kroese FGM, Kallenberg CGM, et al. Leerboek immunologie. Houten: Bohn Stafleu van Loghum; 2016: 493.
7.
go back to reference Chen DS, Mellman I. Oncology meets immunology: The Cancer-Immunity Cycle. Cell, 2013 Jul 25; 39: 1-10. Chen DS, Mellman I. Oncology meets immunology: The Cancer-Immunity Cycle. Cell, 2013 Jul 25; 39: 1-10.
8.
go back to reference Buchbinder E, Hodi FS. Cytotoxic T-lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest, 2015 Sept 1; 125(9): 3377-3383. Buchbinder E, Hodi FS. Cytotoxic T-lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest, 2015 Sept 1; 125(9): 3377-3383.
9.
go back to reference Chen L, Xue H. Anti-PD-1/PD-L1 therapy of human cancer: past, present and future. J Clin Invest, 2015 1; 125(9):3384-3391. Chen L, Xue H. Anti-PD-1/PD-L1 therapy of human cancer: past, present and future. J Clin Invest, 2015 1; 125(9):3384-3391.
10.
go back to reference Haanen J, Carbonnel F, Robert C, et al. Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines. Ann Oncol, 2017: 28 (suppl 4); 119–142. Haanen J, Carbonnel F, Robert C, et al. Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines. Ann Oncol, 2017: 28 (suppl 4); 119–142.
11.
go back to reference Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med, 2016 Jul 4: 14; 272. Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med, 2016 Jul 4: 14; 272.
Metagegevens
Titel
Immuuntherapie
Auteurs
Janneke van der Stap
Anne van Lindert
Publicatiedatum
01-04-2019
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Nursing / Uitgave 4/2019
Print ISSN: 1381-5911
Elektronisch ISSN: 2468-1431
DOI
https://doi.org/10.1007/s41193-019-0062-8